Advanced cfDNA Biomarker for Disease Detection and Severity Assessment
Non-invasive insights into cell destruction for better clinical decisions.
The CFD Test measures cell-free DNA in blood - a marker of how much cell damage is happening in the body. It gives vets a clear, fast way to detect hidden disease, gauge severity, and track treatment progress, from emergencies to long-term care.
How to Use the CFD Biomarker
Clinical Assessment
When you suspect something is wrong, CFD levels help confirm or rule out underlying cellular damage and guide diagnostic decisions.
Treatment Monitoring
Track CFD trends over time to assess treatment effectiveness and adjust protocols based on cellular response.
Annual Checkups
Preventative care through regular testing (annually or bi-annually) to detect rising levels early—like taking blood pressure, but far more powerful and insightful.
Clinical Applications of the CFD Biomarker
Acute Cases
CFD Score Correlates Directly with Severity
Use to stratify patients by severity and guide urgent treatment decisions.
Immediate Results Needed
Coming H2 2026CFD Point-of-Care (POC) necessary for real-time clinical decisions.
Point-of-Care machine coming soon: Our CFD POC device will be commercially available in H2 2026, enabling real-time results for acute cases directly at your clinic.
Use Cases:
- •Internal bleeding
- •Organ failure (single/multiple)
- •Critical care severity assessment
Primary Users: Hospitals / Large clinics with ER / ICU facilities
Chronic Cases
CFD Trend Correlates with Disease Progression
Monitor steep/mild curves vs stable trends to assess disease trajectory.
Results Within Days
CFD POC desirable but not essential for chronic monitoring.
Use Cases:
- •Disease detection (cancer, chronic disease, systemic inflammation)
- •Treatment monitoring (success vs stable vs relapse)
- •Mass assessment (benign vs malignant via initial level + serial sampling trend)
Primary Users: All veterinary clinics for routine and specialized care
Why the CFD Biomarker is Essential for Comprehensive Care
The CFD biomarker works hand-in-hand with traditional biomarkers (such as CRP) to provide a comprehensive picture of your patient's health. By measuring cfDNA levels, veterinarians gain insights into cellular changes happening in the background before they appear as clinical symptoms or abnormalities in routine blood work panels.
Enhanced Diagnostic Clarity:
When cfDNA levels are interpreted together with CRP, they reveal a more complete picture of your dog's health. Low cfDNA and low CRP indicate health, while high cfDNA and low CRP may point to early or hidden diseases that might otherwise go unnoticed, such as early-stage cancer or organ damage.
Non-Invasive Alternative to Invasive Procedures:
The CFD biomarker provides valuable information about cellular health through a simple blood draw, making it a non-invasive alternative to tissue biopsies or expensive imaging solutions, especially when additional information is needed to confirm a health issue.
Proactive Precision Healthcare:
Combining cfDNA with traditional biomarkers (such as CRP) enables veterinarians to detect a wide range of conditions early, from mild inflammation to more serious diseases. This approach supports proactive, personalized care for each dog's unique needs, helping veterinarians make timely, accurate treatment decisions.
Integrating cfDNA and CRP levels provides veterinarians with a powerful tool for understanding health in a nuanced way, empowering them to address potential issues earlier and improve outcomes with a more targeted approach.
How Clinics Use CFD
Seamlessly integrated into your existing blood work workflow with results typically returned within 3-5 business days.
Add CFD to Blood Work Panel
When drawing blood for routine panels (CBC, chemistry), collect an additional 1 ml EDTA plasma and freeze.
Ship Samples Weekly
Batch frozen samples and send via provided shipping materials. Our logistics partner handles pickup and delivery.
Receive CFD Scores & Reports
Access detailed results through our secure veterinary portal with individualized reference ranges and clinical interpretation.
Interpret with Clinical Context
Combine CFD levels with other bloodwork markers (CRP, organ values) for comprehensive diagnostic insights.
Track Trends Over Time
Serial CFD measurements reveal disease progression or treatment response, critical for managing chronic conditions and cancer.
Communicate Results to Clients
Use our clear, owner-friendly reports to explain findings and recommend proactive care plans that build trust and compliance.
Frequently Asked Questions
What is the DeepScan CFD test and how does it work?
The DeepScan CFD test measures circulating cell-free DNA (cfDNA) levels in blood. cfDNA is a biomarker released from damaged or dying cells, and our CFD test reveals elevated levels that correlate directly with cell destruction in the body. This provides veterinarians with critical insights into disease severity, hidden conditions, and treatment effectiveness, from acute emergencies to chronic disease management.
What's the difference between the CFD test and traditional blood markers like CRP?
While CRP and other inflammatory markers indicate inflammation, the CFD test specifically measures cell destruction through cfDNA levels. When interpreted together with CRP, the CFD test reveals a more complete picture: Low cfDNA + low CRP indicates health, while high cfDNA + low CRP may point to early or hidden diseases like early-stage cancer or organ damage that would otherwise go unnoticed.
How is the CFD test performed? Is it invasive?
The CFD test is performed through a simple, non-invasive blood draw, the same as any routine blood test. We analyze EDTA plasma samples using advanced molecular techniques to quantify cfDNA levels accurately. There's no need for tissue biopsies or invasive procedures.
What should I do if CFD test results show elevated levels?
Elevated CFD test results indicate increased cell destruction and warrant further investigation. We provide veterinarians with comprehensive reports that include the CFD score, reference ranges, and guidance for clinical interpretation. A follow-up test is recommended in 2–3 weeks to assess whether cfDNA levels are decreasing, stable, or rising. The next steps depend on the clinical scenario — from immediate interventions in acute cases to additional diagnostics and treatment monitoring in chronic conditions.